Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.81 |
| ▸ | MAPK13 | O15264 | 17/20 | 0.81 |
| ▸ | MAPK12 | P53778 | 17/20 | 0.81 |
| ▸ | MAPK11 | Q15759 | 17/20 | 0.81 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7195956 | 0.90 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL6396818 | 0.87 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11HDAC1 | |
| SCHEMBL2201099 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL7200687 | 0.84 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11HDAC1 | |
| SCHEMBL27482085 | 0.83 | MAPK13 (0.72) | MAPK14MAPK13MAPK12MAPK11HDAC1 | |
| SCHEMBL6653501 | 0.83 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL6820793 | 0.81 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11HDAC1 | |
| SCHEMBL7192088 | 0.81 | MAPK13 (0.76) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL16645313 | 0.81 | HDAC1 (0.57) | MAPK14MAPK13MAPK12MAPK11HDAC1 | |
| SCHEMBL5173305 | 0.81 | MAPK13 (0.61) | MAPK14MAPK13MAPK12MAPK11GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202954-B1 | NOVEL AMINOBENZOPHENONES | LEO PHARMA AS (DK) | 2003-10-01 | — | — | EP | claimed |
| US-6624199-B1 | Prophylaxis and treatment of acne and acne related skin diseases with aminobenzophenones, and novel compounds effective in the treatment, as well as pharmaceutical preparations containing these compounds and dosage units | LEO PHARMACEUTICALS PRODUCTS LTD. A/S (DK) | 2003-09-23 | — | — | US | claimed |
| US-20020165286-A1 | Dermal anti-inflammatory composition | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-11-07 | — | — | US | claimed |
| EP-1202954-A1 | NOVEL AMINOBENZOPHENONES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-05-08 | — | — | EP | claimed |
| WO-2001005744-A1 | NOVEL AMINOBENZOPHENONES | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | claimed |
| EP-1210320-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | disclosed |
| EP-1202954-B1 | NOVEL AMINOBENZOPHENONES | LEO PHARMA AS (DK) | 2003-10-01 | — | — | EP | disclosed |
| US-6624199-B1 | Prophylaxis and treatment of acne and acne related skin diseases with aminobenzophenones, and novel compounds effective in the treatment, as well as pharmaceutical preparations containing these compounds and dosage units | LEO PHARMACEUTICALS PRODUCTS LTD. A/S (DK) | 2003-09-23 | — | — | US | disclosed |
| US-6566554-B1 | Including amino benzothiophenones; useful for treatment of inflammatory diseases in which the production of cytokines is involved in the pathogenesis | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2003-05-20 | — | — | US | disclosed |
| US-20020165286-A1 | Dermal anti-inflammatory composition | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-11-07 | — | — | US | disclosed |
| WO-2002045752-A2 | DERMAL ANTI-INFLAMMATORY COMPOSITION | LEO PHARMA A/S (DK) | 2002-06-13 | — | — | WO | disclosed |
| EP-1210320-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-06-05 | — | — | EP | disclosed |
| EP-1202954-A1 | NOVEL AMINOBENZOPHENONES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001005744-A1 | NOVEL AMINOBENZOPHENONES | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005746-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165286-A1 | Dermal anti-inflammatory composition | CUTA, IL1B, LRBA | MAPK14 644/4885MAPK13 1521/4885MAPK12 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.